Table 3

Adverse events since the initiation of radiotherapy

Treatment-emergent AEsPatients (n=30)
Any gradeGrade 3
Any AE, n (%)29 (96.7)8 (26.7)
 Leukopenia24 (80.0)1 (3.3)
 Reactive cutaneous capillary endothelial proliferation22 (73.3)0
 Radiation proctitis21 (70.0)0
 Anemia20 (66.7)4 (13.3)
 Peripheral neurotoxicity18 (60.0)0
 Neutropenia16 (53.3)4 (13.3)
 Thrombocytopenia16 (53.3)0
 Fatigue13 (43.3)0
 Anorexia10 (33.3)0
 Alanine transaminase increased9 (30.0)0
 Aspartate transaminase increased9 (30.0)0
 Vomiting8 (26.7)0
 Nausea6 (20.0)0
 Hypothyroidism2 (6.7)0
 Abdominal pain2 (6.7)0
 Hand-foot syndrome1 (3.3)0
 Constipation1 (3.3)0
 Diarrhea1 (3.3)0
Immune-related AEs, n (%)*22 (81.5)0
 Reactive cutaneous capillary endothelial proliferation22 (81.5)0
 Hypothyroidism2 (7.4)0
  • *The frequency of immune-related AEs among 27 patients who received at least one dose of camrelizumab was calculated.

  • AE, adverse event.